Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference
03 août 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
11 mai 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
09 mai 2022 16h01 HE
|
Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results...
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
09 mai 2022 16h01 HE
|
Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by...
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022
13 avr. 2022 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
22 févr. 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Announces Management Team Appointments
02 déc. 2021 07h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Present at Piper Sandler’s 33rd Annual Virtual Healthcare Conference
24 nov. 2021 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results
03 nov. 2021 07h00 HE
|
Praxis Precision Medicines, Inc.
Enrollment on track for 1H22 topline results for PRAX-114 Phase 2/3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study PRAX-114 Phase 2 studies in post-traumatic...
Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021
22 oct. 2021 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...